148 related articles for article (PubMed ID: 36779523)
21. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
23. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
24. Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
Hsueh YS; Lin CL; Chiang NJ; Yen CC; Li CF; Shan YS; Ko CH; Shih NY; Wang LM; Chen TS; Chen LT
PLoS One; 2013; 8(6):e65762. PubMed ID: 23840364
[TBL] [Abstract][Full Text] [Related]
25. Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
Roberts KG; Odell AF; Byrnes EM; Baleato RM; Griffith R; Lyons AB; Ashman LK
Mol Cancer Ther; 2007 Mar; 6(3):1159-66. PubMed ID: 17363509
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Yoon DH; Ryu MH; Ryoo BY; Beck M; Choi DR; Cho Y; Lee JL; Chang HM; Kim TW; Kang YK
Invest New Drugs; 2012 Apr; 30(2):819-27. PubMed ID: 21104107
[TBL] [Abstract][Full Text] [Related]
27. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Zhao J; Quan H; Xu Y; Kong X; Jin L; Lou L
Cancer Sci; 2014 Jan; 105(1):117-25. PubMed ID: 24205792
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
Li J; Gao J; Hong J; Shen L
Future Oncol; 2012 May; 8(5):617-24. PubMed ID: 22646775
[TBL] [Abstract][Full Text] [Related]
29. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J
BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647
[TBL] [Abstract][Full Text] [Related]
30. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
31. Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.
Wada N; Kurokawa Y; Takahashi T; Hamakawa T; Hirota S; Naka T; Miyazaki Y; Makino T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Oncology; 2016; 90(2):112-7. PubMed ID: 26779618
[TBL] [Abstract][Full Text] [Related]
32. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
[TBL] [Abstract][Full Text] [Related]
33. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
[TBL] [Abstract][Full Text] [Related]
34. PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.
Gebreyohannes YK; Burton EA; Wozniak A; Matusow B; Habets G; Wellens J; Cornillie J; Lin J; Nespi M; Wu G; Zhang C; Bollag G; Debiec-Rychter M; Sciot R; Schöffski P
Clin Exp Med; 2019 May; 19(2):201-210. PubMed ID: 30523507
[TBL] [Abstract][Full Text] [Related]
35. Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours.
Pantaleo MA; Nannini M; Saponara M; Gnocchi C; Di Scioscio V; Lolli C; Catena F; Astolfi A; Di Battista M; Biasco G;
Anticancer Drugs; 2012 Jun; 23(5):567-72. PubMed ID: 22430048
[TBL] [Abstract][Full Text] [Related]
36. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H
Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
[TBL] [Abstract][Full Text] [Related]
37. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
[TBL] [Abstract][Full Text] [Related]
38. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
Floris G; Debiec-Rychter M; Wozniak A; Stefan C; Normant E; Faa G; Machiels K; Vanleeuw U; Sciot R; Schöffski P
Mol Cancer Ther; 2011 Oct; 10(10):1897-908. PubMed ID: 21825009
[TBL] [Abstract][Full Text] [Related]
39. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A; Bui B
Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
[TBL] [Abstract][Full Text] [Related]
40. BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor.
Tsai HJ; Jiaang WT; Shih NY; Fletcher JA; Lin MJ; Yang MY; Chen CT; Hsu TJ; Wu CC; Lin HY; Chen LT
Cancer Sci; 2018 Nov; 109(11):3591-3601. PubMed ID: 30142229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]